The Molecular Evidence Development Consortium (MED-C)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2015
  • Initiating Organization: Dr. Dane Dickson
  • Initiator Type: Nonprofit foundation
  • Disease focus:
    Cancers
  • Location: North America

Abstract

MED-C is a response to the lack of collaboration between key stakeholders in health care that is holding back progress in the promising domain of personalized medicine. Each of these groups wants what’s best for patient care and recognizes the tremendous potential benefits of personalized medicine, but they have not yet been able to develop a unified approach. MED-C is working to change that. Personalized medicine needs data – lots of it. After consulting with leaders in each of medicine’s major groups, MED-C is developing a registry of genomic data and clinical outcomes from treatments of patients diagnosed with cancer. This data will be readily accessible to physicians, researchers, pharmaceutical companies, regulators, and insurance companies.

Mission

Medical care will become more accurate and precise, time and resources will be better used, money will be put to better use, and more lives will be saved.  MED-C seeks to personalize medicine.

Consortium History

In early 2015, Dr. Dane Dickson, an oncologist from Idaho, saw the need for a new approach to personalized medicine.  He built a collaborative product from the ground up that would fix the most pressing issues of patient disconnect the nation was facing. This product was the MED-C consortium.

Financing

MED-C seeks partnerships, sponsorships and financial support to help them more quickly build an infrastructure that will advance molecular medicine. They welcome donations.

Intellectual Property

The data that is collected by this initiative will be widely available for research by all groups, who working together, can achieve new milestones in cancer treatment

Patient Engagement

MED-C encourages patient engagement as one of the six key groups that must work together to advance personalized medicine.

Impact/Accomplishment

To view MED-C in the news and their accomplishments, click here

Points of Contact

Molecular Evidence Development Consortium
1800 M Street N.W., Suite 1050
Washington DC 20036

Phone: (202) 800-0611

Sponsors & Partners

Genentech

Eli Lilly

Illumina

Thermo Fisher Scientific

Celgene


Last Updated: 06/21/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.